자료실


Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen" by Tong et al.

After reading the article, see the complementary Gastroenterology article.

Abstract:
Background & Aims
During the natural course of chronic hepatitis B virus infection, a small proportion of patients experience hepatitis B surface antigen (HBsAg) seroclearance. However, the long-term clinical outcomes of this process are not well established.

Methods
Thirty-five patients with chronic hepatitis B, followed between 1976 and 2008 at a community liver clinic, experienced HBsAg seroclearance. Ten patients were Caucasian and 25 were Asian. These patients continued to undergo surveillance for hepatocellular carcinoma that included test for α-fetoprotein levels and abdominal ultrasound examinations. The median follow-up time was 185 months (range, 27–400 months).

Results
During the initial visit to the clinic, the median age of the patients was 41 years (range, 1.5–72 years). Eighteen patients (51.4%) were hepatitis B e antigen (HBeAg) positive 25 (71.4%) were hepatitis B virus DNA positive, and 13 (37.1%) had cirrhosis. At the time of HBsAg loss, the median age was 54 years (range, 13–77 years) and all were hepatitis B e antigen- as well as hepatitis B virus DNA negative. During the long-term follow-up, 4 patients with cirrhosis developed hepatocellular carcinoma (HCC), which was discovered by ultrasound examination. Factors associated with development of HCC were low baseline levels of albumin (P = .04), family histories of HBsAg positivity (P = .01) and HCC (P = .04), and age of less than 50 years at the time of HBsAg clearance (P = .03).

Conclusions
HCC can still develop after HBsAg seroclearance. Thus, surveillance should be continued after HBsAg loss in the same manner as for HBsAg positive patients.

Read the Article :  http://www.cghjournal.org/article/PIIS1542356509003723/abstract

Tong MJ, Nguyen MO, Tong LT, et al. Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. Clinical Gastroenterology and Hepatology 2009;7:889-893.

Copyright 2009 AGA Institute
(A) Patient A: a 55-year-old Asian male. (B) Patient B: a 67-year-old Asian male. (C) Patient C: a 69-year-old Caucasian male. (D) Patient D: a 73-year-old Asian male. AFP, alphafetoprotein; ALT, alanine aminotransferase.

Tong MJ, Nguyen MO, Tong LT, et al. Development of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. Clinical Gastroenterology and Hepatology 2009;7:889-893.

Copyright 2009 AGA Institute
번호 제목 글쓴이 날짜 조회 수
164 2009 간세포암종 진료 가이드라인_대한간암연구회, 국립암센터 [1] file 윤구현 2009.09.12 2284
163 2009년 유럽간학회 만성B형간염 관리 가이드라인 [1] file 윤구현 2009.09.12 2921
162 2009년 9월 1일 시행. 헵세라와 바라크루드1mg의 보험급여 변경 내용 [1] file 윤구현 2009.08.31 3086
161 2009년 6월 1일. 페그인터페론(페가시스, 페그인트론) 보험급여 변경 [1] file 윤구현 2009.08.31 1743
160 만성B형간염 - 국민건강보험공단 건강교육 애니메이션 [1] file 윤구현 2009.08.31 1985
» 간암에 대한 최근 흥미로운 저널내용입니다. [5] 양전호 2009.08.22 3880
158 대한의사협회 '급성A형간염 관련 회원 공지사항' [1] 윤구현 2009.07.23 1720
157 판례 : 전염병(HIV감염)을 이유로 국내 체류 외국인에게 출국명령은 부당하다. [1] 윤구현 2009.07.02 1365
156 페그인터페론(페가시스, 페그인트론) 보험급여 기준 변경, C형간염 2,3형 보험적용. 2009년 6월 1일 시행 [1] file 윤구현 2009.06.13 2305
155 심평원심사사례-크레아티닌 청소율 (Creatinine clearance : Ccr) 결과 없이 투여된 레보비르캡슐 인정여부 2008.12.15. [1] 윤구현 2009.06.13 1960
154 심평원심사사례-YMDD mutant 발현시기 비교 헵세라 인정여부 2008.12.15. [1] 윤구현 2009.06.13 1670
153 국립암센터 보도자료] 암 관련 경제적 부담 큰 폭 증가 [1] file 윤구현 2009.06.05 1370
152 식약청발표-레보비르관련 의약품안전성속보 [1] file 윤구현 2009.04.22 2031
151 간암 예방 및 치료 정책의 현황과 개선방안 [1] file 윤구현 2009.04.14 2206
150 '만성간질환 치료의 보험급여 확대의 필요성'. 2009.2.25. [1] file 윤구현 2009.04.09 2154
149 임신시 치료에 대한 정리 [1] 양전호 2009.03.30 2111
148 직장건강검진에서 B, C형 간염 검사 제외 - 건강검진 실시 기준 개정 [1] file 윤구현 2009.02.04 2602
147 스탠포드대학 아시안 간센터에서 만든 브로셔 [1] file 윤구현 2009.01.28 1916
146 만성B형간염치료제들의 가격인하와 보험급여기준 변경 [2] file 윤구현 2009.01.27 3246
145 김창섭 선생님 강의(질문과 답)-"B형간염과 간질환" 2008년4월. (2) [1] 윤구현 2009.01.09 4157